Chronic Rhinitis
Conditions
Brief summary
A multi-center, prospective, non-randomized, observational registry to asses the results of the ClariFix(TM) device when used to ablate unwanted tissue in the nose of subjects with chronic rhinitis.
Interventions
The ClariFix device is a handheld cryosurgical device which provides focal, controlled freezing to the target tissue.
Sponsors
Study design
Eligibility
Inclusion criteria
* Participant is scheduled to receive treatment with the ClariFix device in accordance with the ClariFix Instructions for Use. * Participant is able to provide consent and willing to adhere to the study visit schedule.
Exclusion criteria
* Participant is scheduled to have additional treatment and/or procedures completed at the same time of treatment with the ClariFix device. * Participant is scheduled to have additional nasal or sinus treatments and/or procedures completed within 3 months of treatment with the ClariFix device.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in nasal symptom severity | Follow-up visits at 6 weeks, 3, 6, 9, 12, 15, 18, 21, and 24 months post treatment | Effectiveness will be assessed by the change from baseline in nasal symptoms using the TNSS (Total Nasal Symptom Score). The TNSS is a patient-reported assessment of 4 symptom scores for rhinorrhea (runny nose), nasal congestion, nasal itching, and sneezing. Each symptom is rated on a scale of 0 (none) to 3 (severe). The symptom scores are summed to give a total TNSS score that can range from 0 to 12. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient-assessed improvement in nasal symptoms | Follow-up visits at 6 weeks, 3, 6, 9, 12, 15, 18, 21, and 24 months post treatment | Percentage of participants reporting their change from baseline as minimally improved, much improved, or very much improved using the Patient Global Impression of Change (PGIC) assessment. The PGIC has patients evaluate their improvement over baseline on a scale from 1 (very much improved) to 7 (very much worse). |
| Clinician-assessed improvement in nasal symptoms | Follow-up visit at 3 months post treatment | Percentage of clinicians reporting their participants change in nasal symptoms from baseline as minimally improved, much improved, or very much improved using the Clinical Global Impression - Improvement (CGI-I) assessment. The CGI-I has clinicians rate their patient's improvement over baseline on a scale from 1 (very much improved) to 7 (very much worse). |
Countries
United States